Q1. How many urothelial cancer patients have been treated in the past 3 months with the following agents:
a. Avelumab
b. Atezolizumab
c. Carboplatin with Gemcitabine
d. Carboplatin single or in any other combination
e. Cisplatin with Gemcitabine
f. Cisplatin single or in any other combination
g. Nivolumab
h. Pembrolizumab
i. Any other regimen including Paclitaxel
j. Any other chemotherapy regimen
k. Other active systemic anti-cancer therapy
l. Palliative care only
Q2. How many colorectal cancer [CRC] patients have been treated in the past 3 months with the following agents:
a. Aflibercept
b. Bevacizumab
c. Capecitabine
d. CAPIRI
e. CAPOX (XELOX)
f. Cetuximab in combination with FOLFIRI
g. Cetuximab in combination with FOLFOX
h. Cetuximab not in combination with FOLFIRI or FOLFOX
i. Irinotecan only
j. FOLFIRI
k. FOLFOX
l. Fluorouracil (5FU) only
m. Oxaliplatin only
n. Panitumumab in combination with FOLFIRI
o. Panitumumab in combination with FOLFOX
p. Panitumumab not in combination with FOLFIRI or FOLFOX
q. Pembrolizumab
r. Nivolumab
s. Raltitrexed
t. Ramucirumab
u. Regorafenib
v. Sorafenib
w. Other active systemic anti-cancer therapy
x. Palliative care only
